

✓
Please add the following new claims:

10. A method as defined in claim 2, wherein said azithromycin concentration is from 0.2 to 2.0 weight %.

11. A method as defined in claim 10, wherein said azithromycin concentration is 0.5 weight %.

12. A method as defined in claim 1, wherein said azithromycin is in the form of the dihydrate.

13. A method as defined in claim 1, wherein said ocular infection is trachoma.

14. A composition as defined in claim 5, wherein said azithromycin concentration is from 0.2 to 2.0 weight %.

15. A composition as defined in claim 4, wherein said composition is suitable for application in a regimen comprising once-a-day topical dosing.

16. A composition as defined in claim 4, wherein said azithromycin is in the form of the dihydrate.

17. A composition as defined in claim 4, wherein said ocular infection is trachoma.

REMARKS

As a preliminary matter, attention is directed to the Information Disclosure Statement also included herewith.

The above amendments have been made to further distinguish the invention and to claim further embodiments to which Applicant is entitled.

Claim 4 has been amended to state that the composition for topical eye administration is in the form of an ointment, gel or an ophthalmic solution in isotonic saline. Support is at page 3, line 25; page 3, line 27; and page 4, lines 4-5.

Newly added claim 10 states that in the method defined in claim 2, the azithromycin concentration is from 0.2 to 2.0 weight %. Support is at page 3, line 19.

Newly added claim 11 states that in the method defined in claim 10, the azithromycin concentration is 0.5 weight %. Support is at page 3, line 20.